Journal of Urgent Care Medicine

Head-to-Head Study Compares GLP-1 Weight Loss

In a pharmaceutical head-to-head, tirzepatide was found to provide 47% greater relative weight loss compared to semaglutide. On average, patients using tirzepatide lost 50.3 lbs (22.8 kg), and those using semaglutide lost 33.1 lbs (15.0 kg) after 72 weeks. In addition, for the study’s secondary endpoint, 31.6% of people taking tirzepatide achieved at least 25% body weight loss compared to 16.1% of those taking semaglutide. The randomized, open-label trial included 751 participants across the United …

Semaglutide Keeps Weight Off For Years

Yet another study is underscoring the benefits of semaglutide, as published in Nature Medicine this week. In a cardiovascular outcomes trial involving 17,604 adults with preexisting cardiovascular disease, overweight, or obesity without diabetes, semaglutide showed a 20% reduction in major adverse cardiovascular events. Those treated with semaglutide sustained weight loss for up to 4 years. Authors say improvements in cardiovascular risk factors can begin with weight loss of just 5%, and in the study, semaglutide was …

Semaglutide Approved For Cardiovascular Indications

The FDA approved semaglutide to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and obesity or overweight, according to an agency announcement about the new indication. A phase III study of patients with overweight and obesity showed that semaglutide significantly reduced the composite of cardiovascular death, heart attack, and stroke by 20%. In the 3-year study, these major adverse cardiac events occurred in 6.5% of patients on semaglutide …